AN ACT relating to prescription insulin.

WHEREAS, approximately 450,000 people in Kentucky, or 1 out of every 8 Kentuckians, have been diagnosed with diabetes; and

WHEREAS, an additional 26,000 people in Kentucky are diagnosed with diabetes each year; and

WHEREAS, every Kentuckian with type 1 diabetes and many with type 2 diabetes rely on daily doses of insulin to survive; and

WHEREAS, the cost of treating diabetes increased by 26% from 2012 to 2017, and the annual medical cost related to diabetes in Kentucky now exceeds $5 billion per year; and

WHEREAS, care for people with diabetes accounts for 1 out of every 4 health care dollars spent in the United States; and

WHEREAS, insulin prices rose by 45% between 2014 and 2017, and over the last fourteen years, the price of insulin has increased by 550%, adjusted for inflation; and

WHEREAS, according to research published in the British Medical Journal Global Health, the average cost to produce a vial of insulin is $6; and

WHEREAS, according to the Centers for Disease Control and Prevention, the high price of insulin can lead some patients to begin rationing their diabetes medication or not fully comply with dosing as prescribed by their doctor; and

WHEREAS, a 10% increase in insulin adherence rates can produce up to a 29% decrease in overall health care costs related to diabetes; and

WHEREAS, it is important to enact policies to reduce the costs for Kentuckians with diabetes to obtain life-saving and life-sustaining insulin;

NOW, THEREFORE,

Be it enacted by the General Assembly of the Commonwealth of Kentucky:

Section 1. KRS 304.17A-148 is amended to read as follows:

(1) All health benefit plans issued or renewed on or after the effective date of this
Act[July 15, 1998], shall provide coverage for equipment, supplies, outpatient self-
management training and education, including medical nutrition therapy, and all
medications necessary for the treatment of insulin-dependent diabetes, insulin-using
diabetes, gestational diabetes, and noninsulin-using diabetes if prescribed by a
health care provider legally authorized to prescribe the items.

(2) Diabetes outpatient self-management training and education shall be provided by a
certified, registered, or licensed health care professional with expertise in diabetes,
as deemed necessary by a health care provider.

(3) (a) Except as provided in paragraph (b) of this subsection, the benefits provided
in this section shall be subject to the same annual deductibles or coinsurance
established for all other covered benefits within a given health benefit plan.

(b) Cost sharing, as defined in KRS 304.17A-164, requirements for a covered
prescription insulin drug shall not exceed one hundred dollars ($100) per
thirty (30) day supply of insulin, regardless of the amount or type of insulin
needed to fill the covered person's prescription.

(c) Private third-party payors may not reduce or eliminate coverage due to the
requirements of this section.

Section 2. This Act takes effect January 1, 2021.